Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...
Ahead of the Bengals-Giants game on Sunday, Oct. 13, Jill joined the program to discuss her history with breast cancer and urge viewers to consider genetic testing if they're high risk — a step ...
A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...
Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
“Adult ALL is an extremely aggressive cancer, and there is a high unmet medical need that exists in the treatment of patients ...
An FDA panel on Thursday endorsed a cryoablation system as an alternative to surgery for some early breast cancer patients.
A vaccine against triple-negative breast cancer was found to produce an immune response and was well tolerated by most patients during an ongoing clinical trial. The findings will be presented by ...
Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...
University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer ...
NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Breast cancer rates rose by 1 percent per year from 2012-2021 for all U.S. women combined, with steeper increases for women under 50 and Asian American and Pacific Islander women, according to the ...